Van der Heijde D, et al. Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial. ACR 2018, abstract 1864.
Bimekizumab bij actieve axSpA: effectiviteit en veiligheid over 52 weken
jan 2024 | Spondyloartritis